Register Now for the 2012 ABTA Patient and Family Conference
brain tumor experts will discuss the latest brain tumor research trends and
findings, new and emerging treatment options, and patient/caregiver quality of
life issues at the 2012 ABTA Patient and Family Conference. This annual conference runs from Friday, July 27 through Sunday, July 29 at the Marriot Renaissance Chicago O’Hare Suites Hotel. Sessions will cover topics ranging from
tumor-specific workshops and new imaging techniques to caregiving strategies and
post-treatment wellness. A series of specialized pediatric-focused sessions
will also be offered, as will a pre-conference training track for support group
facilitators. During the event, ABTA-funded researchers will present posters
detailing the scope and results of their efforts. Space is limited, so
early registration is recommended. Click here to register.
Start Spreading the News: Breakthrough for Brain Tumors NYC 5K Run/Walk
You'll want to be a part of the inaugural NYC Breakthrough for Brain Tumors 5K Run/Walk on Saturday, November 10, 2012. The event will take place at Hudson River Park Pier 84, West 44th Street & Hudson River Parkway, New York, NY. Click here to sign up for email notification when registration opens. Registration for our Breakthrough for Brain Tumors 5K Chicago is still open at www.breakthroughforbraintumors.org.
Team Breakthrough: Post-Close Bibs
are Still Available for Chicago Marathon
The Bank of
America Chicago Marathon is sold out, but Team Breakthrough still has post-close
bibs available for anyone interested in running with the team. Do not miss out
on the opportunity to participate in this world class race while making a
difference in the lives of brain tumor patients and their families. You can
move further & move forward with Team Breakthrough. Visit www.abtateambreakthrough.org or
contact Alisha Kassam at firstname.lastname@example.org
or (773) 577-8763.
American Brain Tumor Association Participates in Rare Disease Day
representatives took part in the Food and Drug Administration’s Rare Disease
Patient Advocacy Day on March 1 at the FDA’s offices in Silver Spring,
MD. Participants representing a wide spectrum of rare disease
organizations engaged in a day-long dialogue with FDA officials in sessions
covering the agency’s role in the development of new drugs, biological products
and devices, and discussed efforts currently underway aimed at addressing
nationwide cancer drug shortages.
Do Hormonal Differences
between Males and Females Impact Tumor Growth and Treatment?
from a recently published study, Why Does
Jack and Not Jill Break His Crown, illustrates that males have an increased incidence of both primary and metastatic brain tumors, as compared to females.
The authors theorize that chromosome-based gene expression differences may
occur in the first few days after fertilization, resulting in gender-based
biologic differences in cell-signaling and physiology. These observations add
to the understanding of survival rate differences and treatment responses for
males and females. To read the full article on the differing genetic
characteristics in tumor biology between males and females, click here.
Medulloblastoma May Be Genetically Different from Metastatic Medulloblastoma
international team of researchers, including ABTA Scientific Advisor Michael
Taylor, MD at the Hospital for Sick Children, conducted a study of the genetic
characteristics of primary medulloblastoma tumors and their corresponding
metastatic sites. The research, presented in the February 2012 Nature, reports
that the medulloblastoma metastases are genetically similar, but may not be
identical, to the primary tumor. Since clinical approaches to medulloblastoma
largely assume the primary tumor and its metastases are highly similar, researchers
can now begin to address how these biologic differences may impact treatment
results. The study received partial support through two ABTA Basic Research Fellowships.
To read the abstract online, click here.
Gamma Knife Radiosurgery
and Outcomes for Skull Base Meningioma
recent retrospective study of 255 patients with skull base meningioma concluded
that stereotactic radiosurgery offers a high rate of tumor control and
neurological preservation for patients with skull base meningiomas. The
article, "Gamma Knife Surgery for Skull Base Meningioma", published in the March 2012 Journal of Neurosurgery,
reports long term clinical outcomes (up to 10 years) for these patients. Click here to read more.
Related to Treatment for Primary CNS Lymphoma (PCNSL)
recent study of post-treatment neuropsychological evaluations for 50 patients
with primary CNS lymphoma revealed that cognitive impairments were less
prevalent in PCNSL survivors treated with high dose methotrexate-based
chemotherapy alone versus those who received high dose methotrexate-based
chemotherapy and whole brain radiation therapy. The research, "Cognitive Functions in Primary CNS Lymphoma After Single or Combined Modality Regimes," in the October 2011 Neuro-Oncology, reported
that patients who received the high dose chemotherapy alone had higher scores
across all neuropsychological tests including attention, executive function,
motor speed, and memory. Mild cognitive changes were consistent with the known neurotoxicity
of methotrexate-based chemotherapy treatment, but appeared to have less impact
on quality of life than treatment that included whole brain radiotherapy. For additional study information, click here.
Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to funding brain tumor research. For nearly 40 years, the Chicago-based ABTA has been providing critical funding to researchers working toward breakthroughs in brain tumor diagnosis, treatment and care, and is the only national organization providing comprehensive resources that support the complex needs of brain tumor patients and caregivers.
Make a donation to the American Brain Tumor Association.
This information is provided by the American Brain Tumor Association, 8550 W. Bryn Mawr Ave., Suite 550, Chicago, Illinois, 60631. For more information on the American Brain Tumor Association, call toll-free (866) 659-1030, write email@example.com, or visit www.abta.org.
"American Brain Tumor Association" and "TrialConnect" are registered trademarks of the American Brain Tumor Association. The ABTA logo, the "Breakthrough for Brain Tumors" name and logo, and the "Team Breakthrough" name and logo are trademarks of the American Brain Tumor Association. All rights reserved.
Update Email Preferences | Forward to a Friend | Unsubscribe
©2012 American Brain Tumor Association
Having Fun Raising Funds
April 14, 2012
April 22, 2012
Tuttles Hopkins, MN
April 28, 2012
May 4, 2012
Park Ridge, IL
May 12, 2012
May 12, 2012
June 2, 2012
June 9, 2012
July 7, 2012
July 20, 2012
Columbia Station, OH
hosting an ABTA event? Contact us at firstname.lastname@example.org.
Discover Community Support with ABTA Connections
ABTA's Connections Online Support Community links patients, families, friends, caregivers and health care professionals with each other for support and inspiration. The online community was created to provide a safe place to visit, join and interact with over 500 members of the brain tumor community nationally and around the world.
Find a Clinical Trial Through TrialConnect
The American Brain Tumor Association offers a service that links brain tumor patients with appropriate clinical trials based on tumor type and treatment history. TrialConnect, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Read more.
Our Care Consultants provide brain tumor information, support and education for patients, families and health care professionals. Write
or call our toll-free CareLine at (800) 886-ABTA (2282).